The Global Anxiety Disorder Treatment Market Growth is Driven by Rising Prevalence of Personality Disorders, Mental Health Awareness and Increasing Adoption of Evidence-Based Therapeutics.
Austin, Nov. 20, 2025 (GLOBE NEWSWIRE) — According to SNS Insider, the Anxiety Disorder Treatment Market size was valued at USD 12.89 billion in 2024 and is projected to reach USD 17.57 billion by 2032, growing at a steady CAGR of 3.95% during the forecast period from 2025 to 2032, driven by rising mental health awareness, expanded therapeutic options, and increased access to psychiatric care.
Get a Sample Report of Anxiety Disorder Treatment Market Forecast: https://www.snsinsider.com/sample-request/4182
Anxiety Disorder Treatment Market Overview
The Anxiety Disorder Treatment market has seen consistent growth in recent years as awareness surrounding mental health continues to rise globally. Individuals increasingly seek professional care, which has created elevated demand for established pharmacological therapies and emerging digital therapeutic tools. SSRIs and SNRIs remain the most widely prescribed treatments due to their safety profile and effectiveness, while advancements in psychiatry are introducing new therapeutic options that support long-term management.
Healthcare systems worldwide are integrating telemedicine, expanding outpatient programs, and emphasizing personalized treatment models. This evolution is strengthening access to mental healthcare and contributing to market expansion. As stigma declines and technology adoption rises, the global market is set for steady and sustained growth.
Key Anxiety Disorder Treatment Companies Profiled
- Pfizer Inc.
- Eli Lilly and Company
- GlaxoSmithKline GSK
- Johnson and Johnson
- Merck and Co. Inc.
- AstraZeneca
- Lundbeck AS
- AbbVie
- Takeda Pharmaceutical Co.
- Otsuka Pharmaceutical Co.
- Bausch Health
- Teva Pharmaceutical Industries
- Sun Pharma Industries Ltd.
- Novartis
- Boehringer Ingelheim
- Alkermes plc
- Sage Therapeutics Inc.
- Biogen
- MindMed Inc.
- Compass Pathways plc
Anxiety Disorder Treatment Market Report Scope
| Report Attributes | Details |
| Market Size in 2024 | USD 12.89 Billion |
| Market Size by 2032 | USD 17.57 Billion |
| CAGR | CAGR of 3.95% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Key Segments | • By Type (Antidepressant, Anxiolytics, Antipsychotics, Others)
• By Disorder Type (Generalized Anxiety Disorder, Major Depressive Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Post-Traumatic Stress Disorder, Social Anxiety Disorder) • By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Segmentation Analysis:
By Drug Class
SSRIs and SNRIs dominate the market, collectively accounting for around 60% of global prescriptions, as they effectively target both depression and anxiety disorders with a relatively favorable safety profile. Medications like buspirone are prescribed for generalized anxiety disorder, while moclobemide sees regional adoption for specific anxiety types.
By End-User
Hospitals lead the market, accounting for approximately 55% of treatment revenue, driven by their access to a broad patient base and availability of psychiatrists and treatment facilities. Mental healthcare centers contribute around 30%, providing outpatient services, therapy programs, and ongoing management for chronic anxiety patients.
Need any customization research on Anxiety Disorder Treatment Market, Enquire Now: https://www.snsinsider.com/enquiry/4182
Regional Insights:
With roughly 35–37% of the global market share, North America leads the anxiety disorder treatment industry. High awareness of mental health issues, extensive insurance coverage, and sophisticated healthcare infrastructure all help the area. The main places to receive therapy are hospitals and mental health facilities.
Europe holds around 28–30% of the market share. Growth is fueled by government-led mental health initiatives, rising awareness, and increasing demand for outpatient and community-based care. Key contributors include Germany, the UK, and France. SSRIs remain the most prescribed class, while SNRIs and pregabalin are also widely used.
Recent Developments:
- January 2025 – Johnson & Johnson received FDA approval for SPRAVATO® (esketamine) as the first monotherapy for adults with treatment-resistant depression in the U.S., showing rapid efficacy compared to placebo.
- December 2024 – The FDA approved Eli Lilly’s Zepbound (tirzepatide) for adults with obesity suffering from moderate to severe obstructive sleep apnea, representing a notable advancement in available treatment options in the U.S.
Exclusive Sections of the Report:
- PATIENT ACCESS AND DEMOGRAPHIC INSIGHTS – helps you understand treatment reach across age groups, socioeconomic classes, and insurance coverage levels, providing visibility into disparities and unmet patient needs across regions.
- TREATMENT ADOPTION AND THERAPY LANDSCAPE – helps you evaluate the uptake of pharmaceuticals, psychotherapy, and digital therapeutics, offering insights into evolving treatment preferences such as SSRIs, CBT, and emerging virtual or neuromodulation-based therapies.
- DIGITAL MONITORING AND TELEHEALTH PENETRATION – helps you identify growth opportunities in wearable anxiety-monitoring devices, telehealth platforms, and digital treatment tools, supported by metrics on patient compliance and device adoption rates.
- ECONOMIC BURDEN AND COST STRUCTURE ANALYSIS – helps you understand the financial pressures on patients and healthcare systems through insights on annual treatment costs, out-of-pocket spending, and regional variations in direct and indirect cost burdens.
- TECHNOLOGICAL SHIFT IN BEHAVIORAL HEALTH MANAGEMENT – helps you uncover innovation-driven opportunities through analysis of digital therapeutics, real-time monitoring software, and AI-enabled mental health platforms entering the anxiety treatment ecosystem.
- COMPETITIVE POSITIONING OF THERAPY AND DEVICE PROVIDERS – helps you gauge the strengths of leading players in pharmaceuticals, psychotherapy services, digital tools, and monitoring devices, based on market share and the adoption of new treatment technologies.
Buy a Single-User PDF of Anxiety Disorder Treatment Market Analysis and Outlook Report: https://www.snsinsider.com/checkout/4182
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.